检索结果-南通市图书馆

Radiotherapy among nonagenarians with anal or rectal carcinoma: should we avoid or adapt treatment?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer 2017年第10期36卷 524-525页

作者： Alexis Vallard Chloé Rancoule Jean-Baptiste Guy Avi Assouline Alexander T. Falk Pierre Auberdiac Julien Langrand-Escure cyrus chargari Nicolas Magné Department of Radiotherapy Lucien Neuwirth Cancer Institute 108 BisAvenue Albert.Raimond BP 60008 42271 Saint.Priest En Jarez France Department of Radiotherapy Porte De Saint Cloud Clinical Centre 92100 Boulogne-Billancourt France Department of Radiation Oncology Antoine Lacassagne Centre 06100 Nice France Department of Radiotherapy Claude Bernard Private Hospital 81000 Albi France Department of Radiotherapy Val-De-Grace Military Hospital 75230 Paris France

Dear editor,Radiotherapy is a cornerstone in the management of anal or rectal cancer. Because elderly patients are often excluded from clinical trials, little is known about radiotherapy’s therapeutic index (efficacy/toxicity ratio) in the geriatric population [1]. Still, the ageing of population imposes the challenge to treat older cancer patients and probably to adjust their treatment [2]. A few studies reported data on radiation-induced toxicities in nonagenarian patients, but data on efficacy are still scarce. For rectal cancer, preoperative radiotherapy programs were suggested to be feasible in elderly patients [3–5], with a preference for short protocols without chemotherapy [4]. For anal cancer, the safety of radiochemotherapy was only reported in limited sets of elderly patients [6]. The objective of the present study was to report efficacy and toxicity data on the radiotherapy treatment of nonagenarian patients with anal or rectal *** analyzed the data of 34 nonagenarian patients with anal or rectal cancers: 27 (79.4%) with a rectal adenocarcinoma and 7 (20.6%) with an anal canal squamous cell carcinoma.

关键词： Radiotherapy feasible in elderly patients

Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot study

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Radiology 2013年第6期5卷 248-252页

作者： Nadia Wiazzane cyrus chargari Corine Plancher Jerome Tamburini Bernard Asselain Alain Fourquet Didier Bouscary Youlia M Kirova Department of Radiation Oncology Institut Curie75005 Paris France Department of Biostatistics Institut Curie75005 Paris France Department of Haematology Cochin Hospital75014 Paris France

AIM: To assess the feasibility of the combination of helical tomotherapy(HT) and a concurrent systemic targeted therapy in patients with solitary plasmacytoma (SP) with the aim to decrease toxicity while improving therapeutic efficacy. METHODS: Six patients with biologically, histologically, and radiologically confirmed SP were treated using HT and a systemic targeted treatment concomitantly. Total dose was 40 Gy/20 fractions. Four patients received 4 cycles of concurrent lenalidomide-dexamethasone combination and two patients were treated with concomitant bortezomib-dexamethasone. All toxicities were described using the Common Terminology Criteria for Adverse Effects ***: Five patients had a bone tumor and one patient had an isolated pancreatic mass. Five patients presented with pain, one had neurologic symptoms related to medullary compression, which was treated by an emergency surgery. Median age was 59.5 years (range, 50-74 years). All patients had initial positron emission tomography-computed tomographys, three patients had total body bone magnetic resonance imaging examination, and three patients had computed tomodensitometry scans. The toxicity profile was excellent with no higher than grade 1 toxicity. Four of the six patients experienced a partial radiological response, four had complete response on positions emission tomography and 5/6 patients experienced a complete relief of their symptoms 4 mo after treatment. At a median follow-up of 18 mo, 5/6 patients were controlled clinically, radiologically, and biologically. CONCLUSION: Using HT, we could deliver a highly conformal irradiation concurrently with a molecularly targeted therapy. This association yielded in a high response rate and a low toxicity. A prospective study with longer follow-up will help determining the true benefit of such strategy.

关键词： Plasmacytoma Radiation therapy Targeted treatment Tolerance Lenalidomide Bortezomib

Radiotherapy for gynecologic cancerin nonagenarian patients：a framework for new paradigms

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer 2016年第7期35卷 382-384页

作者： Benoite Mery Sylvie Mengue Ndong Jean-Baptiste Guy Avi Assouline Alexander T.Falk Anais Valeille Jane-Chloc Trone Romain Rivoirard Pierre Auberdiac Alexis Vallard Sophie Espenel Guillaume Moriceau Olivier Collard Claire Bosacki Jean-Philippe Jacquin Guy de Laroche Pierre Fournel cyrus chargari Nicolas Magne Department of Medical Oncology Lucien Neuwirth Cancer Institute42271 Saint Priest En Jarez France Department of Radiotherapy Lucien Neuwirth Cancer Institute42271 Saint Priest En Jarez France Department of Radiotherapy Porte De Saint Cloud Clinical Center92100 Boulogne-Billancourt France Department of Radiotherapy Claude Bernard Private Hospital81000 Albi France Department of Radiotherapy Val-De-Grace Military Hospital75230 Paris France Department of Radiation Oncology Antoine Lacassagne Center06100 Nice France

No consensus exists regarding the role of radiotherapy in the management of gynecologic cancer in nonagenarian *** retrospectively reviewed the outcomes of 19 consecutive nonagenarian patients with gynecologic cancer(6 endometrial cancers,6 cervical cancers,4 vulvar cancers,and 3 vaginal cancers) who were treated with *** was performed mainly in a palliative setting(n = 12;63.2%),with a median dose of 45 Gy(range,6-76 Gy).Infrequent major acute or late toxicities were *** 19 patients,9(47.4%) experienced tumor progression,5(26.3%) experienced complete response,2(10.5%) experienced stable disease and/or partial *** last follow-up,12 patients(63.2%) had died;most deaths(n = 9) occurred because of the *** results suggest that radiotherapy is feasible in the treatment of nonagenarian patients with gynecologic cancer.

关键词：癌症患者妇科放疗放射治疗框架肿瘤患者子宫内膜癌肿瘤治疗

Applications of new irradiation modalities in patients with lymphoma:Promises and uncertainties

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Radiology 2011年第3期3卷 66-69页

作者： Youlia M Kirova cyrus chargari Department of Radiation Oncology Institut Curie 26rue d'Ulm75248 ParisCedex 05France

New highly conformal irradiation modalities have emerged for treatment of Hodgkin *** Tomotherapy offers both intensity-modulated irradiation and accurate patient positioning and was shown to significantly decrease radiation doses to the critical *** we review some of the most promising applications of helical tomotherapy in Hodgkin *** decreasing doses to the heart or the breast,helical tomotherapy might decrease the risk of long-term cardiac toxicity or secondary breast cancers,which are major concerns in patients receiving chest *** strategies,such as debulking radiotherapy prior to stem cell transplantation or total lymphoid irradiation may be clinically ***,helical tomotherapy may also increase the volume of tissues that receive lower doses,which has been implicated in the carcinogenesis *** assessments of these new irradiation modalities of helical tomotherapy are required to confirm the potential benefits of highly conformal therapies applied to hematological malignancies.

关键词： Hodgkin lymphoma Helical tomotherapy Cardiac toxicity Secondary cancers

Could helical tomotherapy do whole brain radiotherapy and radiosurgery?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Radiology 2010年第4期2卷 148-150页

作者： Youlia M Kirova cyrus chargari Sofia Zefkili Franois Campana Department of Radiation Oncology Institut Curie

Whole brain radiotherapy (WBRT) remains the standard management of breast cancer patients with brain metastases, allowing for symptomatic improvement and good local control in most patients. However, its results remain suboptimal in terms of both efficacy and toxicity. In highly selected breast cancer patients, stereotaxic radiotherapy demonstrates a very good local control with a low toxicity. With the purpose of improving the efficacy/toxicity ratio, we report the association of integrated boost with WBRT in a breast cancer patient with brain metastases. Two and a half years after completion of helical tomotherapy (HT), the patient experienced clinical and radiological complete remission of her brain disease. No delayed toxicity occurred and the patient kept her hair without need of radiosurgical procedure. The HT provided a high dosimetric homogeneity, delivering integrated radiation boosts, and avoiding critical structures involved in long-term neurological toxicity. Further assessment is required and recruitment of breast cancer patients into clinical trials is encouraged.

关键词： Brain metastases Radiotherapy Breast cancer Tomotherapy

Concurrent use of aromatase inhibitors and hypofractionated radiation therapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Radiology 2012年第7期4卷 318-323页

作者： cyrus chargari Pablo Castro-Pena Ivan Toledano Marc A Bollet Alexia Savignoni Paul Cottu Fatima Laki Franois Campana Patricia De Cremoux Alain Fourquet Youlia M Kirova Department of Radiation Oncology Institut Curie 75005 Paris France Department of Biostatistics Institut Curie 75005 Paris France Department of Medical Oncology Institut Curie 75005 Paris France Department of Surgery Institut Curie 75005 Paris France

AIM: To retrospectively assess the acute and long-term toxicity using aromatase inhibitors (AI) therapy concurrently with hypofractionated radiotherapy (HFRT) in breast cancer patients. METHODS: From November 1999 to October 2007, 66 patients were treated with breast HFRT and concurrent AI. In 63 patients (95.5%), HFRT delivered a total dose of 32.5 Gy to the whole breast within 5 wk (five fractions, one fraction per week). Other fractionations were chosen in three patients for the patients' personal convenience. A subsequent boost to the tumor bed was delivered in 35 patients (53.0%). Acute toxicities were scored according to the Common Toxicity Criteria for Adverse Events v3. Late toxicity was defined as any toxicity occurring more than 6 mo after completion of HFRT and was scored according to the Late Effects Normal Tissue Task Force-Subjective, Objective, Management and Analytic scale. RESULTS: At the end of the HFRT course, 19 patients (28.8%) had no irradiation-related toxicity. Acute grade 1-2 epithelitis was observed in 46 patients (69.7%). One grade 3 toxicity (1.5%) was observed. With a median follow-up of 34 mo (range: 12-94 mo), 31 patients (47%) had no toxicity, and 35 patients (53%) presented with grade 1-2 fibrosis. No grade 3 or greater delayed toxicity was observed. CONCLUSION: We found that AI was well tolerated when given concurrently with HFRT. All toxicities were mild to moderate, and no treatment disruption was necessary. Further prospective assessment is warranted.

关键词： Breast cancer Hypofractionated radiotherapy Skin toxicity Aromatase inhibitors

Volumetric modulated arc radiotherapy for limited osteosclerotic myeloma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Radiology 2013年第4期5卷 173-177页

作者： Aurélie Robles Antonin Levy Coralie Moncharmont Lamine Farid Jean-Baptiste Guy Nadia Malkoun Lysian Cartier cyrus chargari Isabelle Guichard Jean-Noёl Talabard Guy de Laroche Nicolas Magné Department of Radiotherapy Institut de Cancérologie de la Loire Department of Radiation Oncology Institut Gustave Roussy Université Paris XI Department of Radiation Oncology Hpital d'Instruction des Armées du Val-de-Grace Department of Internal Medicine CHU Saint Etienne

AIM:To assess the feasibility of volumetric intensity-modulated arc radiotherapy (VMAT) in patients with limited polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome. METHODS:A 70-year-old male with histologically confirmed osteosclerotic myeloma was treated in our department in July 2010 with VMAT. Fourty-six Gray in 23 fractions were given on three bone lesions. Doses delivered to target volume and critical organs were compared with a tridimensional conformal radiotherapy (3D-RT) plan. Treatment was well tolerated without any side ***:VMAT improved dose homogeneity within the target volume, as compared to 3D-RT (standard deviations:2.9 Gy and 1.6 Gy for 3D and VMAT, respectively). VMAT resulted in a better sparing of critical organs. Dose delivered to 20% of organ volume (D20) was reduced from 22 Gy (3D-RT) to 15 Gy (VMAT) for small bowel, from 24 Gy (3D-RT) to 17 Gy (VMAT) for bladder and from 47 Gy (3D-RT) to 3 Gy (VMAT) for spinal cord. Volumes of critical organs that received at least 20 Gy (V20) were decreased by the use of VMAT, as compared to 3D-RT (V20 bladder:10% vs 99%; V20 small bowel:6% vs 21%). One year after treatment completion, no tumor progression has been reported. CONCLUSION:VMAT improved dose distribution as compared to 3D-RT for limited osteosclerotic myeloma, with better saving of critical organs.

关键词： Volumetric intensity-modulated arc radiotherapy Conformal radiotherapy Critical organs Osteosclerotic myeloma Polyneuropathy organomegaly endocrinopathy monoclonal gammopathy and skin change syndrome